Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nonrandomized Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

NCT02428296 is registered in ClinicalTrials.gov with National Human Genome Research Institute (NHGRI) as lead sponsor.

NCT NCT02428296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02428296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nonrandomized Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation
Lead sponsor
National Human Genome Research Institute (NHGRI)
Phase
Phase 2
Overall status
Completed
Start date
April 23, 2015
Completion date
February 14, 2018
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genetics, growth disorder, pik3ca-related overgrowth spectrum (pros)